EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of Hepatocellular Carcinoma

Zachary J Brown, Diamantis I Tsilimigras, Samantha M Ruff, Alireza Mohseni, Ihab R Kamel, Jordan M Cloyd, Timothy M Pawlik

JAMA Surgery · 01.04.2023 · 158 (4) · 410

DOI: 10.1001/jamasurg.2022.7989 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA Surgery, erschienen am 01.04.2023. Verfasst von Zachary J Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center, Columbus. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 776-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer-related death worldwide. Recent advances in systemic and locoregional therapies have led to changes in many guidelines regarding systemic therapy, as well as the possibility to downstage patients to undergo resection. This review examines the advances in surgical and medical therapies relative to multidisciplinary treatment strategies for HCC. Observations HCC is a major health problem worldwide. The obesity epidemic has made nonalcoholic fatty liver disease a major risk factor for the development of HCC. Multiple societies, such as the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, the Asian Pacific Association for the Study of the Liver, and the National Comprehensive Cancer Network, provide guidelines for screening at-risk patients, as well as define staging systems to guide optimal treatment strategies. The Barcelona Clinic Liver Cancer staging system is widely accepted and has recently undergone updates with the introduction of new systemic therapies and stage migration. Conclusions and Relevance The treatment of patients with HCC should involve a multidisciplinary approach with collaboration among surgeons, medical oncologists, radiation oncologists, and interventional radiologists to provide optimal care. Treatment paradigms must consider both tumor and patient-related factors such as extent of liver disease, which is a main driver of morbidity and mortality. The advent of more effective systemic and locoregional therapies has prolonged survival among patients with advanced disease and allowed some patients to undergo surgical intervention who would otherwise have disease considered unresectable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansRisk FactorsObesity

Autor:innen und Institutionen

  • Department of Surgery, The Ohio State University Wexner Medical Center, Columbus.
  • Department of Radiology, John Hopkins University, Baltimore, Maryland.

Zitieren

APA

Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023). Management of Hepatocellular Carcinoma. JAMA Surgery, 158(4), 410. https://doi.org/10.1001/jamasurg.2022.7989

Vancouver

Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of Hepatocellular Carcinoma. JAMA Surgery. 2023;158(4):410. doi:10.1001/jamasurg.2022.7989

BibTeX
@article{Brown2023,
  author = {Brown, Zachary J and Tsilimigras, Diamantis I and Ruff, Samantha M and Mohseni, Alireza and Kamel, Ihab R and Cloyd, Jordan M and Pawlik, Timothy M},
  title = {Management of Hepatocellular Carcinoma},
  journal = {JAMA Surgery},
  year = {2023},
  volume = {158},
  number = {4},
  pages = {410},
  doi = {10.1001/jamasurg.2022.7989}
}
Kostenlos starten →